1NOGAI H,DORKEN B,LENZ G.Pathogenesis of non-Hod-gkin's lymphoma[J].J Clin Oncol,2011,29(14):1803-1811.
2FISHER R I,GAYNOR E R,DALBERG S,et al.Comparison of a standard regimen (CHOP)with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J].N Engl J Med,1993,328(14):1002-1006.
2Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cadioprotection in women receiving epirubicin chemotherapy for advanced breast cancer[J]. J clin oncal ,1996,14(5) :3112-3120.
3Lopez M. , Vici P, Di Lauro L, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas[ J]. J Clin Oncol, 1998,16(34) :86-92.
4Speyer J. L, Green MD, Zeleniuch-Jacquotte A, et al. ICRF- 187 Permits longer treatment with doxorubicin in women with breast cancer[ J ]. J Clin Oncol, 1992,10 (5) : 117-127.
5[1]Jaffe ES,Harris N L,Stein H,et al.World Health Organization Classification of Tumor:Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues.France:IARC Press,Lyon,2001,171
6[2]Harris NL,Jaffe ES,Stein H,et at.A revised EuropeanAmerican classification of lymphoid neoplasm:A proposal from the International Lymphoma Study Group.Blood,1994,84:1361
7[3]Katzenberger T,Lohr A,Schwarz S,et al.Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell.Blood,2003,101 (2):699
8[4]Gary-Gouy H,Harriague J,Bismuth G,et al.Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production.Blood,2002,100 (13):4537
9[5]Rosenwald A,Wright G,Chan WC,et al.The use of molecular profiling to redict survival after chemotherapy for diffuse large B-cell lymphoma.N Engl J Med,2002,346:1937
10[6]Shipp MA,Ross KN,Tamayo P,et al.Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.Nat Med,2002,8:68
